RxDoctor Payments DataLook up a doctor →

Raimy Amasha, MD

Pain Medicine · Austin, TXNPI 1760643498

Payments from drug & device makers

$26,061in general payments, 2019–2025

Across 730 payments — averaging $35.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Spinal Simplicity, LLC$3K
  • Lilly USA, LLC$2K
  • Nevro Corp.$2K
  • Boston Scientific$1K
  • AbbVie$942
  • plus $9K from 50 others

What the payments were for

  • Consulting fees$2,2509%
  • Travel & lodging$2,1288%
  • Food & beverage$20,79180%
  • Education$8923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,061 in reported general payments places this provider in the 90th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$653,747
Medicare patients
1,420
Services billed
6,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen925$21,441
BelbucaBuprenorphine Hcl42$16,096
Hysingla ErHydrocodone Bitartrate20$9,844
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$7,053
Pregabalin322$5,778
OxycontinOxycodone Hcl11$4,917
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl47$4,508
Lidocaine45$4,075
Diclofenac Sodium19$3,686
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen155$3,413
Gabapentin307$2,865
Tramadol Hcl ErTramadol Hcl54$2,372
Acetaminophen-CodeineAcetaminophen With Codeine133$2,186
Chlorzoxazone40$1,667
Tramadol Hcl281$1,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$763$16,09642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →